The three IL‐1 inhibitors currently used in clinical practice to treat CAPS are anakinra (Kineret), a recombinant version of the human IL‐1R antagonist protein (IL‐1Ra) canakinumab (Ilaris), a human monoclonal antibody which targets IL‐1β, and rilonacept (Arcalyst), a fusion of the human IL‐1R component (IL‐1R1) and IL‐1R accessory‐protein (IL‐1RAcP) which potently binds IL‐1β and IL‐1α.203. Here, IL1B is linked to cryopyrin-associated periodic syndrome.